RT Journal Article
T1 Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease.
A1 Salvador Martín, Sara
A1 Kaczmarczyk, Bartosz
A1 Alvarez, Rebeca
A1 Navas López, Víctor Manuel
A1 Gallego Fernández, Carmen
A1 Moreno Álvarez, Ana
A1 Solar Boga, Alfonso
A1 Sánchez Sánchez, César
A1 Tolin, Mar
A1 Velasco, Marta
A1 Muñoz Codoceo, Rosana
A1 Rodriguez Martinez, Alejandro
A1 Vayo, Concepción A.
A1 Bossacoma, Ferrán
A1 Pujol Muncunill, Gemma
A1 Fobelo, María J.
A1 Millán Jiménez, Antonio
A1 Magallares, Lorena
A1 Martínez Ojinaga, Eva
A1 Loverdos, Inés
A1 Eizaguirre, Francisco J.
A1 Blanca García, José A.
A1 Clemente, Susana
A1 García Romero, Ruth
A1 Merino Bohórquez, Vicente
A1 González de Caldas, Rafael
A1 Vázquez, Enrique
A1 Dopazo, Ana
A1 Sanjurjo Sáez, María
A1 López Fernández, Luis Andrés
AB Background: Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify pharmacogenomic markers that predict early response to anti-TNF drugs in pediatric patients with IBD. Methods: An observational, longitudinal, prospective cohort study was conducted. The study population comprised 38 patients with IBD aged < 18 years who started treatment with infliximab or adalimumab (29 responders and nine non-responders). Whole gene expression profiles from total RNA isolated from whole blood samples of six responders and six non-responders taken before administration of the biologic and after two weeks of therapy were analyzed using next-generation RNA sequencing. The expression of six selected genes was measured for purposes of validation in all of the 38 patients recruited using qPCR. Results: Genes were differentially expressed in non-responders and responders (32 before initiation of treatment and 44 after two weeks, Log2FC (Fold change) >0.6 or <−0.6 and p value < 0.05). After validation, FCGR1A, FCGR1B, and GBP1 were overexpressed in non-responders two weeks after initiation of anti-TNF treatment (Log2FC 1.05, 1.21, and 1.08, respectively, p value < 0.05). Conclusion: Expression of the FCGR1A, FCGR1B, and GBP1 genes is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD.
PB MDPI
SN 1999-4923
YR 2021
FD 2021-01-06
LK https://hdl.handle.net/20.500.14352/7427
UL https://hdl.handle.net/20.500.14352/7427
LA eng
NO Unión Europea
NO Comunidad de Madrid
NO Instituto de Salud Carlos III
NO Instituto de Investigación Sanitaria Gregorio Marañón
DS Docta Complutense
RD 12 abr 2025